Ventyx Biosciences is Drug Discovery in United States that focus on molecule drug candidates business. Founded in 2018. They cover business area such as developer, small-molecule drug candidate, inflammatory disease, autoimmune disorder, potent, selective small molecule drug candidate, multiple indication, gastrointestinal and dermatological disease, critical autoimmune condition, associate treatment outcome.
2018
( 6 years old in 2024 )
Molecule Drug Candidates
-
662 Encinitas Boulevard
Suite 250
Encinitas, CA 92024
United States
Private
developersmall-molecule drug candidateinflammatory diseaseautoimmune disorderpotentselective small molecule drug candidatemultiple indicationgastrointestinal and dermatological diseasecritical autoimmune conditionassociate treatment outcome
* We use standard office opening hours in near Ventyx Biosciences's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Ventyx Biosciences is Drug Discovery business from United States that founded in 2018 (6 years old in 2024), Ventyx Biosciences business is focusing on Molecule Drug Candidates.
Ventyx Biosciences headquarter office and corporate office address is located in 662 Encinitas Boulevard Suite 250 Encinitas, CA 92024 United States.
Ventyx Biosciences was founded in United States.
In 2024, Ventyx Biosciences is currently focus on molecule drug candidates sector.
Above is snippet of Google Trends for "molecule drug candidates" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Ventyx Biosciences, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
